AZN - AstraZeneca PLC
38.99 +0.04 (0.10%)
After hours: 4:26PM EDT
| Previous Close | 39.29 |
| Open | 39.11 |
| Bid | 38.30 x 4000 |
| Ask | 39.40 x 4000 |
| Day's Range | 38.71 - 39.20 |
| 52 Week Range | 31.99 - 40.16 |
| Volume | 5,896,267 |
| Avg. Volume | 4,039,620 |
| Market Cap | 96.868B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | 36.92 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.74%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | N/A |
- Motley Fool•yesterday
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- Yahoo Finance•2 days ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
- Zacks•2 days ago
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
- Reuters•3 days ago
May says Irish backstop can't derail deadlocked Brexit talks
Prime Minister Theresa May urged the EU on Monday not to allow a stand-off over a 'backstop' for Ireland to derail Brexit talks, saying she believed a deal was still achievable as a top EU official said chances of a no-deal divorce had increased. Addressing a rowdy session of parliament before she headed to Brussels for a summit on Wednesday, May remained upbeat but repeated she would not agree to anything that could split the United Kingdom.
- Reuters•3 days ago
AstraZeneca will keep UK investment freeze if no Brexit clarity
AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
Reuters•3 days agoAstraZeneca will keep UK investment freeze if no Brexit clarity
AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
Reuters•3 days agoNovo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
- Zacks•6 days ago
3 Large-Cap Pharma Stocks Performing Better Than Industry
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
- Zacks•6 days ago
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
- Zacks•7 days ago
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
- Motley Fool•7 days ago
3 Dividend Stocks That Pay You Better Than Pepsi Does
Before you add Pepsi to your income portfolio, you might want to consider these three high-dividend-paying stocks.
- Market Realist•7 days ago
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
- Market Realist•8 days ago
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
- Market Realist•9 days ago
How Novartis’s Businesses Have Been Performing
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
- Zacks•9 days ago
Top Research Reports for JPMorgan, American Express & FedEx
Top Research Reports for JPMorgan, American Express & FedEx
- Market Realist•13 days ago
GW Pharmaceuticals: Q3 Performance, Q4 Estimates
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.
- Market Realist•14 days ago
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.
- Market Realist•15 days ago
Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.
- Motley Fool•16 days ago
2 Stocks That Can Safely Double Your Money
AstraZeneca and Celgene Corporation are both outstanding buys for long-term-oriented investors. Here's why.
- Zacks•17 days ago
Roche Gets FDA Approval for New Formulation of Asthma Drug
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
- Market Realist•17 days ago
How GlaxoSmithKline’s Segments Performed
GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.
Market Realist•18 days agoAstraZeneca: Dividend Overview and Recent Developments
On July 26, AstraZeneca announced a dividend of $0.45, which was paid on September 10. The dividend yield was 3.52%. AstraZeneca paid a dividend of $0.45 on September 10 to shareholders of record on August 10.
- Market Realist•20 days ago
A Look at Eli Lilly’s Revenue Growth Rate
Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.
- Yahoo Finance Video•2 days ago
Drug commercials you see on TV may be overhauled
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.
